BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

...five BGI subsidiaries: BGI Genomics Co. Ltd. (SZSE:300676), BGI Americas Corp., MGI Tech Co. Ltd., MGI...
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

...Huo-Yan or “Fire Eye” laboratory is equipped with high-throughput sequencing equipment manufactured by BGI subsidiary MGI...
BioCentury | May 13, 2019
Financial News

MGI Tech raises $200M for high throughput gene sequencers

...Sequencing technology company MGI Tech raised over $200 million in an undisclosed financing backed by CITIC...
...financing backed by CITIC Goldstone Capital, Green Pine Capital Partners and Orient Securities Capital Investment. MGI...
...NGS-based tests have been founded in China since 2014 (see "China’s Rising Genomics Start-Ups" ). MGI...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

...The takeout is the second orchestrated by Tesaro’s management team. Tesaro CEO Lonnie Moulder lead MGI Pharma Inc....
...cash. Moulder, alongside three other former MGI Execs, formed Tesaro in 2010 (see “NEA Reprises MGI”...
BioCentury | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

...The takeout is the second orchestrated by Tesaro's management team. Tesaro CEO Lonnie Moulder took MGI Pharma Inc....
...acquisition by Eisai Co. Ltd. (Tokyo:4523) for $3.9 billion in cash. Moulder, alongside three other MGI...
BioCentury | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

...The takeout is the second orchestrated by Tesaro's management team. Tesaro CEO Lonnie Moulder took MGI Pharma Inc....
...acquisition by Eisai Co. Ltd. (Tokyo:4523) for $3.9 billion in cash. Moulder, alongside three other MGI...
BioCentury | Jan 9, 2018
Finance

Stars in China

...Ltd. jumped 22% in 4Q17 to reach a market cap of $13 billion. The company’s MGI...
BioCentury | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

...genes that have been correlated as biomarkers that predict recurrence, and Theros Molecular Grade Index (MGI...
BioCentury | Oct 13, 2014
Clinical News

Akynzeo netupitant/palonosetron regulatory update

...the U.S. Eisai gained North American rights to the product through its 2008 acquisition of MGI Pharma Inc....
BioCentury | Oct 11, 2014
Company News

FDA approves Helsinn's Akynzeo combo for CINV

...market Akynzeo in the U.S. It gained North American rights through its 2008 acquisition of MGI Pharma Inc....
Items per page:
1 - 10 of 686
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

...five BGI subsidiaries: BGI Genomics Co. Ltd. (SZSE:300676), BGI Americas Corp., MGI Tech Co. Ltd., MGI...
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

...Huo-Yan or “Fire Eye” laboratory is equipped with high-throughput sequencing equipment manufactured by BGI subsidiary MGI...
BioCentury | May 13, 2019
Financial News

MGI Tech raises $200M for high throughput gene sequencers

...Sequencing technology company MGI Tech raised over $200 million in an undisclosed financing backed by CITIC...
...financing backed by CITIC Goldstone Capital, Green Pine Capital Partners and Orient Securities Capital Investment. MGI...
...NGS-based tests have been founded in China since 2014 (see "China’s Rising Genomics Start-Ups" ). MGI...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

...The takeout is the second orchestrated by Tesaro’s management team. Tesaro CEO Lonnie Moulder lead MGI Pharma Inc....
...cash. Moulder, alongside three other former MGI Execs, formed Tesaro in 2010 (see “NEA Reprises MGI”...
BioCentury | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

...The takeout is the second orchestrated by Tesaro's management team. Tesaro CEO Lonnie Moulder took MGI Pharma Inc....
...acquisition by Eisai Co. Ltd. (Tokyo:4523) for $3.9 billion in cash. Moulder, alongside three other MGI...
BioCentury | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

...The takeout is the second orchestrated by Tesaro's management team. Tesaro CEO Lonnie Moulder took MGI Pharma Inc....
...acquisition by Eisai Co. Ltd. (Tokyo:4523) for $3.9 billion in cash. Moulder, alongside three other MGI...
BioCentury | Jan 9, 2018
Finance

Stars in China

...Ltd. jumped 22% in 4Q17 to reach a market cap of $13 billion. The company’s MGI...
BioCentury | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

...genes that have been correlated as biomarkers that predict recurrence, and Theros Molecular Grade Index (MGI...
BioCentury | Oct 13, 2014
Clinical News

Akynzeo netupitant/palonosetron regulatory update

...the U.S. Eisai gained North American rights to the product through its 2008 acquisition of MGI Pharma Inc....
BioCentury | Oct 11, 2014
Company News

FDA approves Helsinn's Akynzeo combo for CINV

...market Akynzeo in the U.S. It gained North American rights through its 2008 acquisition of MGI Pharma Inc....
Items per page:
1 - 10 of 686